Skip to main content
MRK
NYSE Life Sciences

默克公司口服PCSK9抑制剂恩利西德酯十烷酸酯降低LDL-C 64.6%，获得FDA优先凭证

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$118.06
Mkt Cap
$291.891B
52W Low
$73.31
52W High
$125.14
Market data snapshot near publication time

summarizeSummary

默克公司宣布其研究性口服PCSK9抑制剂恩利西德酯十烷酸酯的2期试验结果极为积极，表明从基线到八周，LDL-C显著降低了64.6%。这一结果显著超过了添加到背景他汀类药物的口服非他汀类治疗的指导方针推荐。进一步增强其潜力的是，FDA在2025年12月选择恩利西德酯十烷酸酯获得专员国家优先凭证，表明监管层的信心和可能的加速审查。这一发展是默克公司管线的一个重要积极因素，提供了一个在大型心血管市场中具有前途的新资产，这在公司面临Keytruda专利到期的未来收入下滑时至关重要。安全性特征与之前的试验一致，显示不良事件无显著差异。投资者现在将关注该药物进入3期试验以及随后的监管里程碑。

在该公告发布时，MRK的交易价格为$118.06，交易所为NYSE，所属行业为Life Sciences，市值约为$2918.9亿。 52周交易区间为$73.31至$125.14。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed MRK - Latest Insights

MRK
Apr 24, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Merck Clears Key Antitrust Hurdle for Terns Pharmaceuticals Acquisition
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 11:50 AM EDT
Source: Reuters
Importance Score:
8
US FDA Approves Merck's New Combination HIV Treatment
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 6:51 AM EDT
Source: Reuters
Importance Score:
8
Merck-Eisai Cancer Therapy Fails Late-Stage Study Goals
Sentiment: Negative
View Wiseek Article
MRK
Apr 20, 2026, 7:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
FDA Grants Priority Review to Merck, Pfizer Bladder Cancer Drug Combo
Sentiment: Positive
View Wiseek Article
MRK
Apr 13, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
Merck Actively Pursues Acquisitions to Bolster Pipeline Ahead of Keytruda Patent Expiration
Sentiment: Positive
View Wiseek Article
MRK
Apr 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Merck Projects Over $70B Pipeline Opportunity, Details Executive Changes and Annual Meeting Proposals
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C 64.6% in Phase 3, Outperforming Competitors
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 11:48 AM EDT
Source: Reuters
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Decanoate Slashes LDL-C by 64.6%, Earns FDA Priority Voucher
Sentiment: Positive
View Wiseek Article
MRK
Mar 29, 2026, 11:49 AM EDT
Source: Reuters
Importance Score:
8
Merck's Winrevair Hits Phase 2 Endpoint, Advancing to Registrational Phase 3 for Pulmonary Hypertension
Sentiment: Positive
View Wiseek Article
MRK
Mar 25, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Merck Acquires Terns Pharma, Bolstering Hematology Pipeline with Novel CML Candidate TERN-701
Sentiment: Positive
View Wiseek Article